Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.36 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26300274 | 0.92 | ALDH1A1 (0.54) | ALDH1A1TSHRLMNAHSD17B10CHRM5 | |
| SCHEMBL15221517 | 0.92 | ALDH1A1 (0.43) | ALDH1A1TSHRLMNAHSD17B10CHRM5 | |
| SCHEMBL1909276 | 0.92 | ALDH1A1 (0.43) | ALDH1A1TSHRLMNAHSD17B10CHRM5 | |
| SCHEMBL14469777 | 0.85 | ALDH1A1 (0.42) | ALDH1A1TSHRLMNAHSD17B10CHRM5 | |
| SCHEMBL65758 | 0.83 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNAHSD17B10CHRM5 | |
| SCHEMBL17401258 | 0.81 | ALDH1A1 (0.48) | ALDH1A1TSHRLMNAHSD17B10CHRM5 | |
| SCHEMBL25587777 | 0.81 | ALDH1A1 (0.48) | ALDH1A1TSHRLMNAHSD17B10CHRM5 | |
| SCHEMBL24177786 | 0.80 | ALDH1A1 (0.61) | ALDH1A1TSHRLMNAHSD17B10CHRM5 | |
| SCHEMBL11722098 | 0.80 | ALDH1A1 (0.61) | ALDH1A1TSHRLMNAHSD17B10CHRM5 | |
| SCHEMBL13039673 | 0.78 | MEN1 (0.42) | ALDH1A1TSHRLMNAHSD17B10CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359375-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9139581-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150038492-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8846928-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140213583-A1 | PI3K Inhibitor for Use in the Treatment of Bone Cancer or for Preventing Metastatic Dissemination Primary Cancer Cells into the Bone | NOVARTIS AG (CH) | 2014-07-31 | — | — | US | disclosed |
| US-8501944-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120142671-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120129867-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142671-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | ALDH1A1 1312/4885TSHR 4257/4885LMNA 2462/4885 |
| US-20120129867-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | ALDH1A1 4344/4885TSHR 2801/4885LMNA 4015/4885 |
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK2 | ALDH1A1 3049/4885TSHR 2944/4885LMNA 4335/4885 |
| US-20140213583-A1 | PI3K Inhibitor for Use in the Treatment of Bone Cancer or for Preventing Metastatic Dissemination Primary Cancer Cells into the Bone | PIK3CA, AKT3, AKT2 | ALDH1A1 3526/4885TSHR 3631/4885LMNA 3150/4885 |
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | ALDH1A1 780/4885TSHR 3127/4885LMNA 2451/4885 |
| US-20150038492-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | ALDH1A1 1312/4885TSHR 4257/4885LMNA 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.